35 results about "Isoleucine+Leucine" patented technology

Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine and hydroxyproline are used as a group II metabotropic glutamate receptor activator; and cysteine is used as a group III metabotropic glutamate receptor activator.

An improved composition for treatment of the skin comprises: (1) methionine and cysteine in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (2) a mixture of essential amino acids in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin, the mixture comprising isoleucine, leucine, lysine, phenylalanine, threonine, tryptophan, valine, histidine, and arginine; (3) at least one antioxidant in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (4) at least one cross-linking agent in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (5) at least one metallic catalyst in a quantity sufficient to accelerate restoration of the integrity and fullness of the skin; (6) at least one transepidermal delivery agent in a quantity sufficient to promote delivery of the composition to the skin; and (7) a topical pharmaceutically acceptable carrier. The antioxidant can be ascorbic acid. The cross-linking agent can be proanthocyanidin or silybin. The metallic catalyst can be Cu (II) in a suitable cupric salt. The transepidermal delivery agent can be benzyl alcohol.

The present invention provides, as a pharmaceutical agent having an effect to inhibit the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, an agent for inhibiting the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, which contains three kinds of amino acids of isoleucine, leucine and valine.

A powdered composition which provides improved muscle growth and helps reduce fatigue, comprising a combination of edible nutritional whey protein, citrulline malate, and at least one branched chain amino acids. The branched chain amino acids are L-isoleucine, L-leucine, and L-valine. The concentration of nutritional protein present in the composition ranges from about 10% by weight to about 96% by weight, and may be about 20% by weight to about 90% by weight. The composition may contain additional ingredients such as polypeptides, a hyper-immune milk protein concentrate, amino acids, antioxidants and various flavorings and sweeteners. A method of use of the composition is also disclosed.

The problem of the present invention is to provide pharmaceutical granules containing, as active amino acid ingredients, three kinds of branched chain amino acids of isoleucine, leucine and valine, which has a smaller specific volume than conventional products, and a production method thereof. As a result of intensive studies, granules containing, as active amino acid ingredients, three kinds of branched chain amino acids of isoleucine, leucine and valine and a production method thereof have been provided, which are characterized by adding an acid to a particle mixture of three kinds of branched chain amino acids of isoleucine, leucine and valine and granulating the mixture, which has solved the above-mentioned problem.

The invention discloses a polyoxometalate compound modified by amino acid.The compound has the general formula of Am[B3XMo6O21].nH2O and is prepared through the steps of dissolving Na2MoO4.H2O, Se, As, Sb or Bi oxide, glycine, alanine, histidine, lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine or arginine and KCl in H2O, putting the solution on a magnetic stirrer to be mixed and stirred, adjusting pH of the solution to be 3.4 to 3.6 through HCl, stirring and heating reflux for 0.5-2 hours, conducting cooling and filtering, standing for 1-2 days, and collecting crystals.It is determined through the MTT method that the IC50 value of HL-60 cells is 0.127 microM, the IC50 value of U937 cells is 2.731 microM, the IC50 value of U937 cells is 2.731 microM, and the IC50 value of HUVECs cells is 889.18 microM.The polyoxometalate compound is high in leukemia resistant activity, low in toxicity and low in price.

The invention discloses an isoflavone derivative modified by acetylaminoacid benzyl ester of a general formula Ia-q, in which R1, R2 and R3 are all CH2CO-AA-OBzl or both R1 and R2 are all CH2CO-AA-OBzl, while R3 is H, wherein the AA in the CH2CO-AA-OBzl is selected from glycin, lactamine, phenyl alanine, tryptophan, isoleucine, leucine, valine, aspartic acid and glutamic acid. The invention also discloses a preparation method of the isoflavone derivative modified by the acetylaminoacid benzyl ester of the general formula Ia-q. The invention adopts an S180 mouse model to evaluate the antitumor effects of the isoflavone derivative modified by the acetylaminoacid benzyl ester of the general formula Ia-q, thus indicating that the isoflavone derivative has excellent antitumor activity and can be used as an antitumor agent.

A pharmaceutical preparation including an amino acid infusion fluid is administered to patients receiving dialysis to ameliorate nutritional status of patients. As a result, anemia can be ameliorated and the required dose of erythropoietin can be reduced in these patients. Furthermore, the serum phosphate levels can be controlled to a predetermined range and protein catabolism can be suppressed in such patients. The amino acid infusion fluid has at least one essential amino acid. The preferred amino acid composition includes at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine, wherein the ratio of essential amino acids to non-essential amino acids is 2.5 or higher.

The invention belongs to the technical field of application of endogenous small-molecule metabolites of biological samples, and provides a combined marker for detecting an anti-depression amount-effect and amount-toxicity relationship of a radix bupleuri petroleum ether part and application of the combined marker. The amount-effect marker comprises L-isoleucine/leucine, L-carnitine, L-acetylcarnitine, adenine and 2-phenylacetamide; the quantity-toxicity marker is prepared from L-carnitine, valine, hydroxysuccinic acid, 2'-adenosine phosphate and 2-sulfuric acid ascorbic acid. The method is used for evaluating the relationship between the anti-depression dose-effect and dose-toxicity of the petroleum ether part of bupleurum chinense, and solves the problem of dose application of the traditional Chinese medicine bupleurum chinense in evaluating the drug effect and safety of depression treatment. The method can be used for sensitively and visually evaluating the relationship between the in-vivo action and dosage of the bupleurum petroleum ether part, and providing technical support for the drug effect and toxic dosage of the traditional Chinese medicine bupleurum, and a new method isprovided for exploring the effectiveness and safety of the traditional Chinese medicine bupleurum.

The invention relates to an affiliative small molecular peptide of an IgG (Immunoglobulin G) antibody. A general formula of the affiliative small molecular peptide is FYX1X2X3X4, wherein F representsphenylalanine, Y represents tyrosine, X1 represents histidine, glutamic acid or the phenylalanine, X2 represents isoleucine, leucine or methionine, X3 represents the glutamic acid, the leucine or glycine, and X4 represents proline, the phenylalanine or the histidine. An affiliative medium derived from the small molecular peptide not only can be used for separation and purification, but also can beused for drug coupling and hemodialysis.

The invention relates to a culture type virus preserving fluid capable of being sterilized by irradiation. The culture type virus preserving fluid mainly comprises the following main components of sodium chloride, magnesium sulfate, potassium chloride, magnesium chloride, disodium hydrogen phosphate, potassium dihydrogen phosphate, 4-hydroxyethyl piperazine ethanesulfonic acid, arginine, cysteine, glutamine, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, glucose, sucrose, vitamin C, vitamin E, amphotericin B, gentamicin, streptomycin, penicillin and phenol red. The preserving fluid can maintain the phenol red indicator to be red under the irradiation intensity as high as 20kGy, and plays a role of a pH indicator after subsequent sampling; and the preserving fluid can be used for directly preserving virions collected in throat swabs, nose swabs or specific part tissue samples, and is used for subsequent culture or nucleic acid extraction experiments.

The invention discloses an in-vitro energy supply substance suitable for skin collagen synthesis, a raw material and a preparation method. The in-vitro energy supply substance comprises proline or L-proline; a serine or an L-serine; an alanine or an L-alanine; an isoleucine or an L-isoleucine; a leucine or an L-leucine; aspartic acid or L-aspartic acid; tyrosine or L-tyrosine; glutamic acid or L-glutamic acid; phenylalanine, or L-phenylalanine; arginine hydrochloride or L-arginine hydrochloride; lysine hydrochloride or L-lysine hydrochloride; a valine or an L-valine; threonine, or L-threonine; histidine hydrochloride or L-histidine hydrochloride; tryptophan, or L-tryptophan; a methionine or an L-methionine; cystine or L-cystine; glycine; hyaluronic acid; tranexamic acid; glucose; sodium hydrogen sulfite or rosmarinic acid; dimethylaminoethanol; and the balance of water for injection. The traditional Chinese medicine composition can supplement water, preserve moisture, tighten and lift the skin, relieve skin sagging and improve fine lines, wrinkles, aging and the overall texture and color of the skin.

The invention discloses an antibacterial peptide LJ-2 and an application thereof. The amino acid sequence of the antibacterial peptide LJ-2 is as follows: the amino acid sequence of the antibacterialpeptide LJ-2 is shown in the specification: arginine, arginine, valine, leucine, arginine, isoleucine, leucine, lysine, histidine, histidine, glutamine, glycine, leucine, isoleucine, arginine, asparagine, leucine and leucine; the antibacterial peptide LJ-2 has good antibacterial activity on gram-positive bacteria, gram-negative bacteria and fungi, and has the advantages of low hemolysis, heat resistance, salt resistance, acid and alkali resistance and repeated freeze thawing resistance. Therefore, the antibacterial peptide LJ-2 disclosed by the invention has a wide application prospect in thefields of anti-infective drug preparation, animal husbandry development, human disease prevention and treatment, food preservation, detergents, cosmetics and the like.

The invention discloses a function and application of oxidase in bicyclomycin biosynthesis, and particularly provides oxidases BcmB, BcmC, BcmD, BcmE, BcmF and BcmG in bicyclomycin biosynthesis and the application of the six oxidases in a multi-step oxidation reaction for catalysis adopting isoleucine-leucine cyclic dipeptide (cIL) as a primary substrate to obtain bicyclomycin biosynthesis finally. The method can be applied to in-vitro efficient production of bicyclomycin or analogues, wherein cyclic dipeptide is adopted as starting raw materials.

The invention relates to the technical field of cosmetics, and discloses a cosmetic composition with a skin care effect and a preparation method thereof. The cosmetic composition comprises the following components in percentage by mass: 60.45% of deionized water, 3% of glycerol, 0.2% of allantoin, 0.3% of betaine, 0.25% of serine, 3.5% of glycine, 3% of alanine, 1% of arginine, 2% of aspartic acid, 2% of valine, 2.5% of isoleucine, 0.5% of leucine, 1% of glutamic acid, 1% of proline, 3% of threonine, 2.5% of histidine, 0.1% of methionine, 0.3% of cystine and 2% of tyrosine. , 2.5% of crithmum maritimum, and 1% of fibroin. According to the cosmetic composition with the skin care effect and the preparation method of the cosmetic composition, the cosmetic composition is simple in component, easy to prepare and long-lasting in moisturizing effect, in addition, due to the synergistic effect of the composition, water locking and moisturizing can be conducted on the skin, the skin barrier function can be better enhanced, and the repairing effect of the cosmetic reaches the best.

The invention belongs to the technical field of biology, and particularly relates to a pure natural compound amino acid small molecule active peptide extracted from plants and an extraction method, a preparation and application thereof. The pure natural compound amino acid small molecule active peptide extracted from Nostoc Sphaeroides comprises 16 compound amino acids, which are aspartic acid, serine, glutamic acid, glycine, histidine, arginine, threonine, alanine, proline, valine, methionine, lysine, isoleucine, leucine, phenylalanine and tryptophan. The first purpose of the invention is to provide a pure natural compound amino acid small molecule active peptide extracted from Nostoc Sphaeroides. The second purpose is to provide a method for extracting the pure natural compound amino acid small molecule active peptide from plants; the third purpose is to provide a preparation of the pure natural compound amino acid small molecule active peptide; the fourth purpose is to provide application of the pure natural compound amino acid small molecule active peptide.

An infusion preparation which is to be used in dialyzing a dialysis patient for ameliorating the anemic state by improving nutritional conditions, thus reducing the dosing amount of erythropoietin, controlling the serum phosphorus level to thereby regulate the serum phosphorus level within a definite range and inhibiting the protein catabolism and which contains at least essential amino acids, characterized in that the amino acids are composed of at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine and the ratio of essential amino acids : non-essential amino acids is 2.5 or higher.